4547 — Kissei Pharmaceutical Co Income Statement
0.000.00%
- ¥172bn
 - ¥125bn
 - ¥88bn
 
- 58
 - 45
 - 88
 - 74
 
Annual income statement for Kissei Pharmaceutical Co, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.
2021 March 31st  | 2022 March 31st  | 2023 March 31st  | 2024 March 31st  | 2025 March 31st  | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M | 
| Source: | Yuho | Yuho | Yuho | Yuho | Yuho | 
| Standards: | JAS | JAS | JAS | JAS | JAS | 
| Status: | Final | Final | Final | Final | Final | 
| Revenue | |||||
| Total Revenue | 69,044 | 65,381 | 67,493 | 75,579 | 88,330 | 
| Cost of Revenue | |||||
| Gross Profit | 32,723 | 31,238 | 32,375 | 37,341 | 44,065 | 
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 66,893 | 67,223 | 68,556 | 71,257 | 85,762 | 
| Operating Profit | 2,151 | -1,842 | -1,063 | 4,322 | 2,568 | 
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 7,476 | 16,507 | 13,680 | 14,449 | 15,610 | 
| Provision for Income Taxes | |||||
| Net Income After Taxes | 5,378 | 13,032 | 10,634 | 11,290 | 11,976 | 
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | 5,285 | 12,922 | 10,529 | 11,162 | 11,962 | 
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 5,285 | 12,921 | 10,528 | 11,160 | 11,961 | 
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 103 | 288 | 226 | 240 | 334 | 
| Dividends per Share |